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Abstract
Sleep-disordered breathing (SDB) worsens over pregnancy, and obstructive sleep apnea is
associated with serious maternal complications. Intrauterine exposures that provoke insulin
resistance (IR), inflammation, or oxidative stress may have long-term offspring health consequences. In obesity, worsening maternal SDB appears to be an exposure that increases the risk
for both small- or large-for-gestational-age (SGA, LGA, respectively), suggesting distinct outcomes linked to a common maternal phenotype. The aim of this paper is to systematically
review and link data from both mechanistic rodent models and descriptive human studies
to characterize the impact of maternal SDB on fetal development. A systematic review of
the literature was conducted using PubMed, Embase, and CINAHL (01/2000–09/2019).
Data from rodent (9 studies) and human models (48 studies, 5 meta-analyses) were included
and reviewed using PRISMA guidelines. Evidence from rodent models suggests that intermittent maternal hypoxia results in mixed changes in birth weight (BW) followed by accelerated
postnatal growth, while maternal sleep fragmentation results in normal BW followed by later
metabolic derangement. Human studies support that maternal SDB is associated with both SGA
and LGA, both of which may predispose offspring to later obesity. Evidence also suggests a link
between SDB, inflammation, and oxidative stress that may impact maternal metabolism and/or
placental function. SDB is common in pregnancy and affects fetal growth and development.
Given that SDB has significant potential to adversely influence the intrauterine metabolic
environment, larger, prospective studies in humans are urgently needed to fully elucidate
the effects of this exposure on offspring metabolic risk.

Introduction

© Cambridge University Press and the
International Society for Developmental
Origins of Health and Disease 2020.

Disturbed sleep is a known risk factor for metabolic dysregulation but in pregnancy, it remains
under-recognized and poorly understood. Altered sleep patterns due to normal physiologic
changes in pregnancy are common, but can be debilitating. They may pose significant risk to both
the mother and developing fetus, particularly in obese women with commonly co-occurring risk
factors. Disturbed sleep is implicated in a multitude of serious maternal/fetal complications that
are exacerbated in obesity. These include gestational hypertension and preeclampsia,1–9 gestational diabetes mellitus,10,11 preterm birth, and unplanned cesarean delivery.12,13 Sleep-disordered
breathing (SDB) is one of the most common sleep disorders and impacts up to 32% of
pregnancies.14
By definition, SDB is a continuum that ranges from mild inspiratory flow limitation to
obstructive sleep apnea (OSA) (see Dempsey et al. [2010]).15 Mild SDB is characterized by snoring from inspiratory flow limitation.16 OSA is the most severe form of SDB in which partial or
complete collapse of the upper airway results in decreased airflow (hypopnea) or cessation of
breathing (apnea) and frequent arousals.17 Loud snoring and somnolence (excessive daytime
sleepiness) are common features of OSA. Apneas and hypopneas result in sleep fragmentation
(SF) to restore airway patency. While the development of SDB is likely multifactorial, one of its
strongest predictors is obesity18; increasing fat in airway muscles and neck fat pads19 make collapse of the upper airway more likely. Investigators have consistently reported that frequency of
self-reported snoring increases through pregnancy.3,20 This is likely due to the anatomical and
physiological changes associated with pregnancy, such as increased blood volume, gestational
weight gain, and increasing abdominal pressure due to the enlarged uterus.21
Obesity is a state of insulin resistance (IR) in most individuals.22,23 Pregnancy itself produces
an IR state as a normal adaptation to ensure an adequate supply of maternal fuels to the meet the
metabolic demands of the placenta and growing fetus. IR in pregnancy is largely a result of
placental hormones such as human placental growth hormone, human placental lactogen,
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increased levels of Tumor Necrosis Factor-alpha, and decrease in
adiponectin.24,25 With increasing fetal growth, IR is maximal in the
late 2nd and 3rd trimesters when there is an approximate 50%
decrease in insulin-mediated glucose disposal and a 200%–300%
increase in insulin secretion in response to glucose.26,27 It has
been demonstrated that women with obesity enter pregnancy
with heightened IR, upon which the effects of pregnancy are
additive.26–29
Pregnancy IR may be exacerbated by worsening SDB. Although
the association between IR and SDB is likely bidirectional,30 there is
evidence suggesting that sleep disruption similar to that experienced in severe SDB precedes altered insulin sensitivity and glucose
metabolism, suggesting causality.31–34 The exact mechanisms
underlying this relationship are not understood, but several
hypotheses have been proposed. SF and intermittent hypoxia
(IH) may increase IR through over-activation the sympathetic
nervous system (SNS),35–37 activation of the hypothalamicpituitary-adrenal axis with increased cortisol release,38 or increased
inflammation and reactive oxidative stress.39,40 Interestingly, IH,
increased inflammation, and increased oxidative stress, particularly early in pregnancy, can also impair placental function and
blood flow.41 Thus, it is possible that the duration and severity
of SDB results in opposite growth outcomes to the fetus. Mild
SDB that worsens over pregnancy may exacerbate pregnancy IR,
resulting in nutrient over-exposure and offspring large-forgestational age (LGA). In contrast, preexisting chronic OSA may
increase risk of endothelial dysfunction and hypertensive disorders
in pregnancy, result in abnormal placentation with reduced blood
flow, and lead to earlier delivery and offspring small-for-gestational
age (SGA). Both LGA and SGA are risk factors for childhood
metabolic disease. Fig. 1 highlights the potential mechanisms by
which SDB may exacerbate both IR and changes at the placenta.
Both animal and human models support that in utero development is a time of tremendous plasticity during which the fetus is
exquisitely sensitive to exposures within the intrauterine environment. In accordance with the Developmental Origins of Health
and Disease (DOHaD) framework, in utero plasticity allows for
the creation of environmentally matched phenotypes that are best
suited to promote survival under altered conditions, such as underor overnutrition, or IH.42 These phenotypes, however, are vulnerable
to dysregulation with reversal of those conditions postnatally (i.e., an
environmental mismatch). After birth, a background of preset functional capacity and gradual loss of plasticity, in combination with an
obesity-promoting postnatal environment, is thought to set the stage
for offspring obesity and chronic disease risk.42,43 During pregnancy,
maternal factors such as nutrient intake, metabolic disturbances,
and hypoxia shape fetal environmental conditions; even normal
variation in these exposures is now appreciated to have long-term
offspring consequences. Sleep may influence these maternal factors,
affecting fetal development and growth. Birth weight (BW) and
body composition, specifically increased fat mass at birth, are strong
predictors of future metabolic disease.44 Emerging data continue to
demonstrate that low and high BWs predict higher odds for
overweight/obesity in school-aged children (OR 1.91–2.34),45 and
fat mass at birth is a stronger predictor of childhood obesity risk
than BW.44
Childhood obesity in the United States affects nearly one in five
preschool children, suggesting a role for early environmental
factors.46 Because the risk for childhood obesity appears to be
propagated by a number of in utero environmental conditions,
and SDB is common, a better understanding of its potential impact
on fetal outcomes might inform interventions that optimize the
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intrauterine environment, mitigating chronic disease risk beginning during fetal development. Accordingly, the aim of this paper
is to systematically review and link data from both mechanistic
rodent models and descriptive human studies to characterize the
impact of maternal SDB on fetal development. While the data suggest that SDB in pregnancy may be an exposure to the developing
fetus, we emphasize that controlled, appropriately designed, and
prospective data are required to provide stronger support for this
relationship. Significant confounders in human investigations,
potential reasons for discrepant findings, and suggested areas
for future research are also discussed.
Methods
PubMed, Embase, and CINAHL were searched using terms that
included: “sleep disordered breathing” OR “obstructive sleep
apnea” OR “snoring” OR “sleep fragmentation” OR “intermittent
hypoxia” AND “pregnancy” OR “placenta” OR “fetus” OR “infant”
OR “birthweight”. Original studies were included if: (1) full text
was available; (2) written in English; (3) publication was between
01/2000 and 09/2019; and (4) infant outcomes were reported (e.g.
BW, intrauterine growth restriction [IUGR], small or large for gestational age [SGA, LGA, respectively]) in relation to SDB. Animal
studies were included if the disruptions common to SDB (SF or IH
during the sleep period) were used in pregnant animals and metabolic outcomes of the offspring were assessed. Notably, only studies where IH, not chronic hypoxia, were included because in the
human condition, SDB is limited to IH during the sleep period.
PRISMA guidelines were followed for the review. Quality of studies
was reviewed using the NIH tool for observational studies and
NIH tool for case–control studies47 in humans and the SYRCLE
tool48 for animal studies. For human studies, control for the major
confounders of maternal age, gestational age, BMI, gestational
hypertension, diabetes, and smoking was assessed in each study.
Results
Fig. 2 shows the flow of study selection. Initially, a total of 1374
abstracts were retrieved from the 3 databases. After careful review,
57 articles (48 in humans and 9 in rodents) in which assessment of
maternal SDB during pregnancy with fetal, placental or infant
birth-weight outcomes were included. Additionally, five meta
analyses met criteria for inclusion and were reviewed. All studies
in humans were descriptive or case–control studies. Table 1
provides information on studies reviewed in rodents, and
Table 2 provides information on studies reviewed in humans.
The quality review of human studies is summarized in Table 3.
Supplementary Table S1 provides quality ratings of the animal
studies.
Rodent models of gestational SDB show metabolic
aberrancies in offspring growth and development
Rodent models (mice and rats) of the effects of gestational SDB
allow for mechanistic investigation of the independent effects of
SF and IH as separate exposures to the developing offspring. In
the human SDB condition, it is not possible to isolate the effects
of IH vs SF due to co-occurrence and interacting effects. While
all of the studies in rodents were randomized control trials, most
of the reports lack description of the key bias indicators such as
similarity of groups at baseline, sequence generation and random
housing (Table S1).
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Fig. 1. Sleep-disordered breathing in pregnancies affected by obesity: two offspring phenotypes. Pregnancy is a state of increased insulin resistance (IR) and increasing weight
which exacerbates both SDB symptoms and preexisting IR of obesity. Preexisting IR is understood to be multifactorial and known mechanisms are listed. SDB involves intermittent
hypoxia, sleep fragmentation, or a combination, which activate pathways that further increase IR. Severe SDB, manifested as OSA, may result in extreme sleep fragmentation and
intermittent hypoxia that alters placental development. In extreme cases, altered placental functioning may lead to small-for-gestational age (SGA) infants. However, exacerbation of IR due to worsening SDB also may result in excessive fetal-placental nutrient exposure, leading to large-for-gestational age (LGA) infants. Alternatively, exposure to SDB
and increased IR may result in newborns born with normal birthweight but increased adiposity or subclinical alterations in metabolism. Developmental Origins Theory posits that
risk of future disease is along a continuum with both extremes (both SGA and LGA) leading to increased risk of future disease. AA, amino acids; BW, birthweight; FFA, free fatty
acids; IR, insulin resistance; OSA, obstructive sleep apnea; ROS, reactive oxygen species; SDB, sleep disordered breathing; SNS, sympathetic nervous system; GLP-1, glucagon-like
peptide-1; HGP, hepatic glucose production; AT, adipose tissue; SM, skeletal muscles; HPA, hypothalamic pituitary adrenal axis.

Fig. 2. Prisma flow diagram for selection of articles.

Intermittent hypoxia: Investigators reported either no difference in BW,49,50 significantly lower BW51 or growth restriction52
in offspring exposed to gestational IH during pregnancy compared
to control animals. In two studies, IH-exposed offspring had lower
BW but rapid catch-up growth,51,52 which has been shown to be

related to increased risk of childhood obesity in humans.53 At
6–12 weeks of life, male offspring exposed to gestational IH had
greater fat mass compared to controls.52 Khalyfa et al. found that
male, but not female, offspring exposed late gestational IH (days
13–18 of gestation) had higher body weight and visceral adipose
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Table 1. Overview of studies conducted in rodents
Sleep fragmentation (SF)
Author, year

Outcomes

Findings

Body fat, insulin resistance, visceral fat, epigenome of
adipose tissue in offspring into adulthood in mice

SF exposed offspring had altered methylation patterns in genes
related to obesity/metabolic syndrome (Akt2, Cartpt, Apoe),
increased body fat, and insulin resistance which lasted into
adulthood

Khalyfa 201456

Body weight, glucose, insulin, fat mass, DNA
methylation of Adiponectin gene in mice offspring

Increased body weight, body fat, and adiponectin gene methylation
in SF exposed offspring in adulthood

Khalyfa 201557

Glucose, insulin, fat mass, metabolic gene expression,
and methylation patterns in mice offspring

Worse metabolic profiles in males exposed to SF, not females

Mutskov 201555

FOXO1 gene regulation, body weight, body fat, glucose,
and insulin in mice offspring

Increased histone methylation and acetylation of FOXO1 gene
promoter, increased body fat, and glucose/insulin in SF exposed
offspring; physical activity early in life reversed changes

Trzepizur 201759

Body weight, glucose, insulin, fat mass, DNA
methylation of adiponectin gene of mice offspring in
adulthood; effect of SF on double mutant CHOP and
GADD4 in mice offspring

Body weight, adipose tissue, glucose, and insulin higher in SF
exposed offspring. No effect of SF on double mutant mice

Cortese 2015

54

Intermittent hypoxia (IH)
Author, year

Outcomes

Findings

Gozal 200351

Metabolic rate, body weight of offspring in rats

IH exposed offspring had significantly lower birthweight but rapid
catchup growth, no changes in metabolic rate

Iqbal 201352

Growth restriction, body fat, glucose, insulin of offspring
in rats

IH exposed offspring were growth restricted at birth, had increased
insulin, glucose and body fat into adulthood

Body weight of offspring in rats

No difference between IH and no IH exposure

Lipid profiles, insulin resistance, adipose tissue
methylation in mice offspring

Higher body weight in adulthood, insulin resistance and lipid
profiles, and altered adipose tissue gene methylation in SF-exposed
males but not females

McDonald 201650
Khalyfa 2017

49

tissue at 24 weeks compared to controls.49 HOMA-IR and plasma
leptin were higher, and plasma adiponectin was lower in these male
offspring exposed to maternal IH compared to controls at
24 weeks,49 suggesting that there may be sex differences in exposure outcomes. The investigators further reported upregulation
of gene methylation pathways associated with energy production
in adipose tissue of IH-exposed offspring, suggesting a potential
mechanism by which IH-exposure may result in increased risk
of obesity.49
Sleep fragmentation. Exposure to SF in utero may have deleterious effects on offspring metabolism which do not manifest until
later in life. In mouse offspring exposed to gestational SF, BW
was not different than controls.54–56 However, as the mice entered
adulthood (16–18 weeks of life), offspring of SF-exposed mothers
had significantly higher mean body weight, fat mass, blood glucose,
and higher fasting total triglyceride and cholesterol concentrations
than controls.55,56 The negative metabolic effects of gestational SF
on offspring were more pronounced in males, once again, supporting sex differences.57 Similar to IH, changes in gene methylation
patterns for PPARα activation (critical for fatty acid oxidation,
ketogenesis,58 and hepatic gluconeogenesis) were seen in male
offspring exposed to SF compared to controls.57 In a separate study,
offspring exposed to gestational SF had epigenetic changes resulting in overexpression of the FoxO1 gene, a transcription factor that
plays an important role in gluconeogenesis and glycogenolysis.55
Taken together, these findings suggest that SF exposure, especially
in males, changes the offspring’s ability to regulate glucose and
lipid metabolism, increasing risk of future metabolic disease.
Alterations in offspring metabolism may, in part, be due to an

integrated stress response involving cortisol and sympathetic activation.59 Offspring of double mutant mice of integrated stress
response genes CHP and GADD34 (unable to mount a stress
response) exposed to SF did not have metabolic perturbations as
seen in normal mice offspring exposed to SF.59 Importantly, postnatal physical activity implemented early in SF-exposed offspring
reduced FoxO1 acetylation and methylation to levels similar to
controls.55
The evidence from rodent models is compelling; however, it
must be underscored that unlike humans, mice and rodents are
born with very little fat and size at birth is in part due to the size
of the litter and driven more by lean body mass. In summary, evidence from these rodent models suggests distinct mechanisms
whereby maternal IH results in normal or low BW and subsequent
accelerated postnatal growth, and maternal SF results in normal
BW followed by later metabolic derangement.
Human studies: strong link between SDB and birthweight
outcomes
Over 30 published reports described a strong association between
maternal SDB and birth outcomes in humans, supporting that
mechanisms and outcomes in rodent models may have translational relevance. In accordance with the DOHaD model, infants
born with IUGR/SGA or LGA are both at risk for future metabolic
diseases such as obesity and T2D.60 Notably, while the purpose and
study population were clearly defined in most reports, most lacked
power for infant outcomes, made a single assessment of SDB
during pregnancy (instead of multiple measures over gestation),
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Table 2. Overview of studies conducted in humans in which the association between SDB and infant growth outcomes was examined
Study author
and year
Ayrum, 2011

1

Bassan, 201690
Bin, 201693
Bourjeily, 2010
Chen, 2012

4

9

Facco, 201469
Farabi, 201995
Franklin, 2000

Outcome(s)

Type of assessment
for SDB

Study design

Timing of
assessment SDB

400

Birth weight

Self-report snoring

Cross-sectional

Labor

−

44

Birth weight;
neurological exam

Questionnaire and
WatchPAT

Prospective

2nd trimester

−

636,227

LGA, SGA

ICD9 code

Retrospective

Previous year

þLGA, −SGA

1000

LBW, SGA

Self-report snoring

Cross-sectional

Labor

−

4746

LBW, SGA

ICD9 code

Retrospective

Previous year

þ

188 (1st trimester) SGA, LGA
128 (3rd trimester)

WatchPAT

Prospective

1st and 3rd
trimesters

−

Sample size

7

Fung, 201331

Findings

18

%body fat

WatchPAT

Prospective

3rd trimester

±

502

SGA

Questionnaire

Retrospective,
cross-sectional

Labor

þ

Questionnaire and PSG

Prospective

3rd trimester

þ

371 Questionnaire SGA/fall in growth
41 PSG
percentile >33%

þLGA, þMacrosomia,
−SGA

Ge, 201680

3079

SGA, LGA, LBW

Questionnaire

Prospective

1st and 3rd
trimesters

Guilleminault,
200091

267

BW

Questionnaire

Prospective

1st trimester

Howe, 201594

633

SGA, LGA

Questionnaire

Prospective

3rd trimester

Higgins, 201188

4074

Birthweight

Questionnaire

Prospective

Labor

SGA/fall in growth
percentile >33%

PSG

Retrospective

All gestations

þ

SGA

Questionnaire

Prospective

3rd trimester

−

Kneitel, 201867
Ko, 201370

276

Leung, 2005

92

247

BW

Questionnaire

Prospective

1, 2, 3rd trimesters

Louis, 201012

57

Birth weight, SGA

PSG

Prospective

All trimesters

Louis, 201287

175

Birth weight

PSG

Prospective

All trimesters

66

þ LGA
þ Birth weight

−
þ Birth weight; −SGA
−
−

poor fetal growth

ICD9 code

Retrospective

Not defined

Micheli, 201164

1091

LBW, SGA

Questionnaire

Prospective

3rd trimester

þLBW, −SGA

Miyagawa, 201168

179

SGA

Oxygen saturation

Prospective

3rd trimester

1/22 infants born SGA in
OSA group (4.5%); 4/157
in no OSA group (1.5%)

O’Brien, 201313

1689

SGA,LGA

Questionnaire

Prospective

3rd trimester

þ

439

SGA, LGA

Questionnaire

Prospective

3rd trimester

Louis, 2014

Okun, 2018

55,781,965

−

81

220

SGA

Questionnaire

Prospective

1st trimester

−

84

232

LBW

Questionnaire

Cross-sectional

Labor

−

65

Olivarez, 201171
Owusu, 2013

þLGA (comorbid
insomnia and snoring);
−SGA

230

SGA

PSG

Prospective

3rd trimester

þ

Perez-Chada,
200772

447

SGA

Questionnaire

Cross-sectional

Labor

−

Pien, 201485

105

LBW

PSG

Prospective

1st and 3rd
trimesters

−

Ravishankar,
201573

148

Birth weight, IUGR,
placental hypoxia

ICD9 codes for OSA,
questionnaires snorers
and controls

Retrospective
case-control

Delivery for
snorers and
controls/OSA was
previous year

Sahin, 200874

316

Birth weight

PSG

Prospective

3rd trimester

þ

Sarberg, 201475

500

SGA

Questionnaire

Prospective

1st and 3rd
trimesters

−

Sharma, 201686

209

LBW

Questionnaire

Prospective

1, 2, 3rd trimesters

−

Pamidi, 2016

þ Birth weight, þ IUGR,

(Continued)
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Table 2. (Continued )
Study author
and year
Spence, 2017

Sample size
76

305,001

Outcome(s)

Type of assessment
for SDB

Poor fetal growth

ICD9 Code

Retrospective
Cohort

previous year

Study design

Timing of
assessment SDB

Findings
−
−

Tauman, 201277

246

LBW, SGA

Questionnaire

Cross-sectional

Labor

Telerent, 201879

155

LGA, SGA

WatchPAT

Prospective

3rd trimester

þ LGA, −SGA

Ugur, 201289

465

Birthweight

Questionnaire

Prospective

3rd trimester/
Labor

±(p = 0.055)

Yin, 200878

178

IUGR

Oxygen saturation

Prospective

3rd trimester

Bourjeily, 2015102

190

Fetal markers of
well-being

ICD9 code

Case–control

previous year

Estriol lower in OSA;
AFP not different after
BMI adjusted

Bourjeily, 2015102

190

Placental markers
of angiogenesis and
well-being

ICD9 code

Case-control

Previous year

PAPP-A lower in OSA

Khan, 201799

64

Oxidative and
carbonyl stress

ICD9 codes for OSA,
questionnaire for
controls

Case–control

Previous year

Lower stress markers in
OSA

Kidron, 2019105

53

Placental length,
weight, thickness.
Gene expression of
VEGF, VEGF receptor,
leptin, and PIGF

WatchPAT

Prospective

3rd Trimester

Higher placental weight
of women with OSA
(n = 10) after BMI
controlled for. Leptin
gene expression higher
in placenta of OSA

Koken, 200797

83

Oxidative and
carbonyl stress

Questionnaire

Prospective, case- 2nd or 3rd
control
trimester

GSH lower and MDA
higher in snorers

Olivarez, 201096

100

Fetal heart rate

PSG

Prospective

3rd trimester

No correlation between
fetal heart rate and OSA
symptoms

Salameh, 2018104

313

Markers of fetal and
placental Wellbeing

Questionnaire

Cross-sectional

Labor

No difference in
markers of fetal well
being between snorers
and non snorers

Salihu, 2015106

67

Telomere length

Questionnaire

Cross-sectional

Labor

Shorter telomeres in
OSA

Tauman, 201198

122

Fetal erythropoiesis

Questionnaire

Cross-sectional

Labor

þ Erythropoiesis, IL-6,
and EPO with OSA

Tauman, 2015108

62 (2 days)
52 (1 year)

Infant
neurodevelopment

Questionnaire and
WatchPAT

Prospective

2nd trimester

−Birth weight,
−Neurodevelopmental
changes

−

Mechanistic studies

Negative finding (−); Positive finding (þ); Trend (±); IUGR, intrauterine growth restriction; LBW, low birth weight; LGA, large for gestational age; SGA, small for gestational age.

did not measure severity of SDB, and body composition at birth
was rarely measured (Table 3). In 32 of the 48 studies, investigators
attempted to at least partially control for important confounding
variables: maternal age, gestational age, BMI, smoking, and preexisting hypertension, which could highly influence growth outcomes (Table 3). It is also notable that all humans studies are
descriptive in nature, so cause and effect cannot be determined.
Further, even after attempting to control for known confounders,
there may still be unmeasureable or unknown variables which can
influence study outcomes.
IUGR/SGA. 27 studies were reviewed in which SGA or IUGR
were reported as outcomes, three of which were meta-analyses.
Ding et al. reported a significant association between SDB and
IUGR across 8923 women in 11 studies (OR = 1.44 [95% CI:

1.22–1.71]).61 Similarly, Warland et al. reported by meta-analysis
that SGA was significantly associated with SDB across 9478
women (13 studies) in which SDB was measured subjectively
(adjusted OR = 1.6 [1.1–2.2]) and across 56,423,715 women
(7 studies) which included objective measures (adjusted
OR = 1.4 [1.1–1.9]).62 In contrast, Brown et al. found no significant
association between SDB and SGA by meta-analysis of 21 studies
(adjusted OR 1.19, [0.94–1.51]).63 Findings were mixed across the
24 original (non-meta-analysis) studies reviewed for this manuscript. While investigators reported an association between SDB
and growth restriction in nine studies,7,9,13,31,64–68 no significant
association was detected across 15 studies.4,12,69–81 Mixed findings
may be due to lack of consistent assessment of SDB, the severity of
the SDB and provocation of IH, and a lack of adequate power
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Table 3. Quality review of human studies included in systematic review
Observational studies
Study author and year
Ayrum 2011

1

Bassan, 2016

90

Bin, 201693
Bourjeily, 2010
Chen, 2012

4

9

Facco, 201469
Farabi 201995
Franklin, 2000
Fung, 2013

7

31

Ge, 201680
Guilleminault, 200091
88

Q1

Q2

Q3

Q4

Q5

Q6

Q7

Q8

Q9

Q10

Q11

Q12

Q13

Q14

Y

Y

NR

Y

N

N

N

N

N

N

Y

NR

NA

N

Y

Y

NR

Y

N

Y

Y

N

Y

N

Y

Y

NR

N

Y

Y

NA

Y

N

Y

CD

N

Y

N

Y

NR

NA

Y

Y

Y

Y

Y

N

N

N

Y

Y

N

Y

NR

Y

Y

Y

Y

NA

Y

N

Y

CD

N

Y

N

Y

NR

NA

Y

Y

Y

Y

Y

N*

Y

Y

Y

Y

Y

Y

NR

Y

N

Y

Y

NR

Y

N*

Y

Y

Y

Y

N

Y

NR

N

Y*

Y

Y

NA

Y

N

N

CD

N

N

N

Y

NR

NA

Y*

Y

Y

N

Y

N

Y

Y

N

Y

N

Y

NR

Y

Y

Y

Y

Y

Y

N*

Y

CD

Y

N

Y

Y

NR

Y

Y

Y

Y

NR

Y

N

Y

Y

Y

Y

N

Y

NR

NR

N

Y

Y

NR

Y

N*

Y

CD

N

Y

N

Y

NR

NA

N

Howe, 201594

Y

Y

Y

Y

N

Y

N

N

Y

N

Y

NR

NR

Y*

Kneitel, 201867

Y

Y

NR

Y

Y

Y

CD

N

Y

N

Y

NR

NA

Y

Y

Y

Y

Y

N

Y

CD

N

Y

N

Y

NR

Y

Y*

Y

Y

NR

Y

N*

Y

Y

Y

Y

Y

Y

NR

Y

N

Louis, 2010

12

Y

Y

NR

Y

N

Y

CD

N

Y

N

Y

NR

NR

Y

Louis, 2012

87

Y

Y

N

Y

N*

Y

CD

N

Y

N

Y

NR

Y

Y

Louis, 201466

Y

Y

NA

Y

N

N

CD

N

Y

N

Y

NR

NA

Y

Y

Y

NR

Y

N

Y

Y

Y

Y

N

Y

NR

NA

Y*

Y

N

NR

Y

N

Y

Y

N

Y

N

Y

NR

NR

Y*

Y

Y

Y

Y

Y

Y

CD

Y

Y

N

Y

NR

NA

Y

Y

N

NR

Y

N

Y

CD

N

Y

N

N

NR

NA

Y

Y

Y

Y

Y

Y

N

Y

N

Y

NR

N/A

Y*

Higgins, 2011

Ko, 2013

70

Leung, 200592

Micheli, 2011

64

Miyagawa, 2011

68

O’Brien, 201313
Okun, 2018

81
71

Y

Y

84

Y

Y

Y

Y

N

N

N

N

Y

N

N

NR

Y

N

Pamidi, 201665

Y

Y

N

Y

Y

Y

CD

Y

Y

N

Y

NR

Y

Y*

Perez-Chada, 200772

Y

N

NR

Y

N

N

CD

N

Y

N

Y

NR

NA

Y

Y

Y

NR

Y

Y

Y

Y

Y

Y

Y

Y

NR

Y

Y

Y

Y

NR

Y

N

Y

CD

N

Y

N

Y

NR

NR

N

Sarberg, 201475

Y

Y

NR

Y

N

Y

Y

Y

N

Y

N

NR

N

N

86

Y

Y

Y

Y

N

Y

Y

N

Y

Y

Y

NR

Y

N

Spence, 201776

Y

Y

NA

Y

N

N

Y

N

Y

N

Y

NR

NA

Y

77

Y

Y

NR

Y

N

N

N

Y

N

N

Y

NR

NA

Y*

79

Olivarez, 2011
Owusu, 2013

Pien, 2014

85

Sahin, 200874

Sharma, 2016

Tauman, 2012

Y

Y

NR

Y

N

Y

CD

N

Y

N

Y

NR

Y

Y

Ugur, 201289

Y

Y

NR

Y

N

Y

CD

N

Y

N

Y

NR

NR

N

Yin, 200878

Y

Y

NR

Y

Y

N

CD

Y

Y

N

Y

NR

NA

N

Case-Control Studies

Q1

Q2

Q3

Q4

Q5

Q6

Q7

Q8

Q9

Q10

Q11

Q12

Ravishankar, 201573

Y

Y

N

Y

Y

Y

NR

N

N

Y

Y

N

Telerent, 2018

Mechanistic studies
Observational Studies

Q1

Q2

Q3

Q4

Q5

Q6

Q7

Q8

Q9

Q10

Q11

Q12

Q13

Q14

Kidron, 2019105

Y

Y

NR

Y

N

Y

Y

N

Y

N

Y

NR

NR

Y

Salameh, 2018104

Y

Y

N

Y

N

N

CD

N

Y

N

Y

NR

NA

N
(Continued)
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Table 3. (Continued )
Observational studies
Study author and year
Salihu, 2015

106

Tauman, 2011

98

Q1

Q2

Q3

Q4

Q5

Q6

Q7

Q8

Q9

Q10

Q11

Q12

Q13

Q14

Y

Y

NR

Y

N

N

CD

N

Y

N

Y

Y

NA

N

Y

Y

NR

Y

N

N

CD

Y

Y

N

Y

NR

NA

Y

Tauman, 2015108

Y

Y

NR

Y

N

Y

CD

N

Y

N

N

NR

NA

Y*

Olivarez, 201096

Y

Y

NR

Y

Y

N

CD

N

Y

N

Y

NR

NA

Y*

Case-Control Studies

Q1

Q2

Q3

Q4

Q5

Q6

Q7

Q8

Q9

Q10

Q11

Q12

Bourjeily, 2015102

Y

Y

N

N

Y

Y

NR

N

N

Y

NR

Y*

101

Y

Y

N

N

Y

Y

NR

N

N

Y

NR

Y*

Y

Y

N

Y

Y

Y

NR

N

N

N

NR

Y

Y

Y

N

Y

Y

Y

NR

N

Y

Y

NR

N

Bourjeily, 2015
Khan, 2017

99

Koken, 2007

97

Y = Yes; N = No; NR = Not Reported; NA = Not Applicable; N*=power analysis reported but not for outcome of interested; Y*=partial control of confounders
(maternal age, gestational age, BMI, hypertension, diabetes, or smoking)
Descriptive Studies:

Q1. Research question or objective in this paper clearly stated?; Q2. Study population clearly specified and defined?; Q3.
Participation rate of eligible persons at least 50%; Q4. All subjects selected or recruited from similar populations? Inclusion/
exclusion criteria prespecified and uniformly applied?; Q5. Sample size justification or power estimate?; Q6. Were the
exposure(s) measured prior to the outcome(s)?; Q7. Timeframe sufficient so one could reasonably expect to see an association
between exposure and outcome?; Q8. Exposures that vary in amount or level, did study examine different levels of exposure
as related to outcome?; Q9. Exposures clearly defined, valid, reliable, and implemented consistently?; Q10. Exposure assessed
more than once?; Q11. Outcome measures clearly defined, reliable, and implemented consistently?; Q12. Outcome assessors
blinded to exposure?; Q13. Was loss to follow-up after baseline 20% or less?; Q14. Were potential confounding variables
(maternal age, gestational age, BMI, hypertension, diabetes, or smoking) measured and adjusted for?

Case-Control Studies

Q1. Research question or objective in this paper clearly stated and appropriate?; Q2. Study population clearly specified and
defined?; Q3. Include a sample size justification?; Q4. Controls selected or recruited from same/similar population that gave
rise to cases?; Q5. Definitions, inclusion/exclusion criteria valid, reliable, and consistently implemented?; Q6. Cases clearly
defined and differentiated from controls?; Q7. If less than 100% of cases and controls selected, were those chosen selected at
random?; Q8. Use of concurrent controls?; Q9. Able to confirm exposure/risk occurred prior to development of condition or
event defined as case?; Q10. Measures of exposure/risk clearly defined, valid, reliable, and consistently implemented?; Q11.
Assessors of exposure/risk blinded to status of participants?; Q12. Key potential confounding variables (maternal age,
gestational age, BMI, hypertension, diabetes, or smoking) measured and adjusted for?

Studies were reviewed using the NIH tools for observational or case–control studies.

(Table 3). Timing of maternal SDB assessment varied widely across
studies with the majority of subjective SDB assessment done at
time of delivery. Type of SDB assessment was also highly varied;
the majority of studies included self-reported symptoms of snoring, which does not reflect severity of SDB. Of the 19 studies, only
five13,31,65,71,78 were powered to detect an association between SDB
and SGA as the primary outcome; a positive association was
reported in three of the studies and no association was reported
in two (Table 2). In the majority of the studies (n = 20), investigators controlled (at least in part) for important maternal variables
(BMI, hypertension, diabetes, smoking) that could influence infant
growth outcomes (Table 3). Studies in which severity of OSA is
measured objectively throughout gestation (pre-pregnancy
through 3rd trimester) in relation to SGA are lacking. In summary,
the results from descriptive studies in humans are mixed in support
of an association between SDB and SGA which may be due to a lack
of consistency of measurement of SDB, a lack of power or other
confounding variables that were not measured.
BW: Results from three meta-analyses supported a relationship
between SDB and low BW with similar ORs (OR = 1.75 [95% CI:
1.33–2.32],61 1.67 [1.0–2.78],63 1.39 [1.14–1.65]82), while Li et al.
concluded that there was no association between SDB and BW in
a meta-analysis across 8749 women (15 studies).83 OSA diagnosis
(documented by ICD-9) was associated with an increased risk of
low BW (<2500 g; OR = 1.76 [1.28–2.40], n = 4746).9 Further,

self-reported frequent snoring in the 3rd trimester was associated
with low BW (RR = 2.6 [1.2–5.4]); however, after adjustment for
pre-maturity, snoring was no longer associated with low BW.64
SDB was not associated with increased risk of low BW in three
smaller studies,84–86 none of which were powered for BW as the outcome. Louis et al. reported that compared to women with obesity
alone, women with OSA had infants with significantly lower BW
(3288 ± 590 vs. 3013 ± 968 g).12 Diagnosis of OSA was made either
before or during pregnancy and continuous positive airway pressure
use/adherence was not reported, important because treatment of
OSA could have affected BW in the OSA group. In three studies
where BW was compared between women with OSA and those
without, one group of investigators reported higher BW in women
with OSA71 and two reported no significant difference.74,87 Higgins
et al. reported significantly higher BW in infants of women with a
positive Berlin Score (high risk of OSA),88 but Ugur et al. reported
slightly lower BW in infants of women with a positive Berlin score.89
Discrepant findings may be due to multiple factors. There was
inconsistent timing of SDB measurement throughout the studies
from pre-pregnancy to delivery, severity was not consistently
assessed, and the degree of IH was usually unreported. BW was used
differently across studies; five of the studies used low BW (<2500 g)
as a categorical variable9,64,84–86 (requiring a larger sample to detect
an association), while the other 10 studies used BW as a continuous
variable.1,71,74,77,87,90–92 Further, none of the studies were powered on
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the BW outcome and body composition was not assessed.
Importantly, low BW is different from IUGR as it is not corrected
for gestational age (i.e., a preterm infant is expected to have a lower
BW but may or may not have growth restriction). In seven of the
studies found, investigators made an effort to at least partially adjust
for confounding factors, while in nine of the studies, there was no
control for confounding factors (Table 3). In summary, overall
results from studies support an association between SDB and low
BW, but, in over half of the studies, potential confounding variables
were not controlled thus limiting the strength of evidence to support
this association.
LGA: One meta-analysis supported an association between SDB
and LGA across 678,310 women (7 studies) (OR = 1.6 [95% CI:
1.3–1.9]),62 while the additional four meta-analyses did not include
LGA as an outcome. In eight studies, investigators reported an
association between SDB and LGA.13,69,79–81,93,94 Seven groups
found a significant association between SDB symptoms and
LGA (BW > 90th percentile) and one group reported a significant
association between SDB and macrosomia (defined as BW > 97th
percentile). Maternal diagnosis of OSA in the year before or during
pregnancy (across 636,227 women) was significantly associated
with increased risk of LGA in a large, retrospective cohort
(adjusted OR = 1.27 [1.04–1.55], p < 0.05), after adjustment for
obesity.93 Similarly, women who self-reported apnea had increased
frequency of LGA compared to women who denied apnea (22.4%
vs. 12.8%, p = 0.049).13 Maternal report of pregnancy-onset
breathing pauses during sleep was associated with LGA
(OR = 3.5 [95% CI: 1.3–9.6], p = 0.01).94 OSAþ women (identified
via ICD-9 codes) had higher rates of macrosomia (BW > 97th percentile), but this group had a significantly higher rate of maternal
diabetes and higher body mass index (BMI) which could also
explain the macrosomia rate.73 Telerent et al. reported that the
occurrence of LGA was significantly more frequent in infants born
to mothers who had mild sleep apnea compared to those who did
not.79 The investigators studied women in their 3rd trimester and
excluded women with more severe sleep apnea (apnea hypopnea
index [AHI] > 15), which might be expected to result in placental
insufficiency and attenuated growth.79 Facco and colleagues, on the
other hand, did not find an association between OSA (diagnosed
using in-home objective measurement) and LGA (19.4% LGA in
no SDB group vs. 12.5% in Moderate/Severe SDB group).69 The
lack of significant finding for this study may be due to the fact that
it was designed to look at maternal and not fetal outcomes and a
higher cutoff for definition of LGA (>95th percentile). Across
studies, there are limited data on the classes of obesity, and no measures of newborn body composition. We recently completed a
study in which we examined the relationship between severity of
maternal OSA and infant % body fat in maternal obesity (BMI
30–40). There was no correlation between severity of OSA (by
AHI) and infant % body fat (r = 0.34, p > 0.05)95; however, overnight minimum oxygen saturation was correlated with infant %
body fat, suggesting that increasing severity of maternal OSA (with
greater reduction oxygen saturation) was related to higher newborn fat (r = −0.63, p = 0.02).95 Importantly, none of the studies
were powered on LGA, the assessment of SDB symptoms were variable and often did not include the degree of hypoxia, and the timing of assessment across studies was inconsistent. However, in
seven of the eight studies, investigators attempted to control for
confounding factors (Table 3). The available evidence supports
an association between more severe maternal SDB and fetal overgrowth even after controlling for maternal BMI (in most studies).

245

Clinical studies investigating potential mechanisms
Some investigators studied the relationship between SDB in pregnancy and biomarkers that may indicate potential mechanisms for
the link between SDB in pregnancy and fetal outcomes.
SDB and fetal stress. Maternal apneas were accompanied by
fetal heart rate decelerations in three of four women with
OSA,74 suggesting increased fetal stress with maternal apnea. In
contrast, Olivarez and colleagues found no association between
degree of oxygen saturation and fetal heart rate in 20 women with
OSA (severity of OSA not reported).96
SDB, inflammation and oxidative stress. Koken and colleagues97
reported that markers of oxidative stress (maldondialdehyde
[MDA], Myeloperoxidase [MPO]) were higher and an anti-oxidant
marker (Glutathione peroxidase [GSH-Px]) was lower in plasma of
women who reported snoring compared to non-snorers. Of note,
women who snored were older with higher BMI, which may confound the relationships reported, and the gestational week of blood
collection was not controlled. In another study, women who reported
snoring during pregnancy (n = 48) had higher levels of the inflammatory cytokine IL-6 in cord blood compared to women who denied
snoring (n = 75).98 Erythropoietin and nucleated (immature) red
blood cell counts were higher in the cord blood of women who
reported snoring,98 supporting that exposure to SDB in utero may
result in hypoxic changes in the fetus. In contrast, Khan and colleagues reported in a retrospective study that women with diagnosed
OSA (vs. self-reported non-snorers) had lower oxidative and carbonyl
stress markers (Advanced glycation end products [AGE] and
advanced oxidation protein products [AOPP]), but higher antioxidative stress markers (total antioxidant capacity [TAC]).99
Taken together, these findings support that SDB, and especially
OSA, may increase fetal exposure to oxidative stress, inflammation,
and hypoxia-induced compensatory enhanced erythropoiesis, however further study is warranted as the findings are inconsistent.
This is interesting as inflammation and oxidative stress may
exacerbate IR.100,101
SDB and placental changes. Placental expression of carbonic anhydrase IX (CAIX), a marker of hypoxia, was higher in women who
snored or with OSA compared to non-snoring women
(n = 47).73 Fetal normoblastemia (immature red blood cells), a sign
of exposure to hypoxia, was significantly higher in placentas of
women who snored/had OSA. However, women who snored and
women with OSA had significantly higher BMI and higher rates of
chronic hypertension and diabetes (vs. non-snorers), which likely
contributed to differences in biomarkers (preeclampsia rates were
similar between groups).73 Women with OSA had lower levels of
placenta-associated plasma protein-A (PAPP-A)102 and lower estriol
levels103 compared to women without OSA, suggesting poorer placental and fetal well-being, which could affect growth. Salameh et al.,
however, showed no differences in markers of fetal well being
(PAPP-A, AFP, uE3, hCG, inhibin-A) between snorers and nonsnorers.104 Women with mild OSA (mean AHI 7.8 ± 2.7), objectively
measured in the 3rd trimester, had significantly higher placental
weight and higher placental leptin mRNA expression compared to
women without OSA, even after controlling for maternal BMI.105
Placental weight was positively correlated with infant adiposity (measured by skinfolds).105 This was a small study and a power analysis was
not reported; however, the findings support that mild OSA may result
in placental changes that contribute to increased infant adiposity. The
effect of OSA on maternal IR was not explored in any of these studies
as a possible mechanism for the increased in adiposity.
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SDB and chronic disease risk. Salihu and colleagues reported
that women at high risk of OSA (measured by Berlin
Questionnaire) had neonates with shorter telomeres than women
at low risk of OSA (n = 64 women).106 Telomere length is indicative of chromosomal aging and has been proposed as a mechanism
contributing to chronic disease development,107 suggesting that
exposure to OSA could have long-term implications in accordance
with DoHad theory.42
Long-term implications of SDB exposure in humans. In a single
longitudinal study, BW between infants born to mothers with SDB
were similar to controls.108 However, despite similar neurological
development, at 1 year, mothers with SDB vs. control were more
likely to report infant snoring (41.7% vs. 7.5%, p = 0.004).108
Human studies in which body composition of the infant, and
longer term metabolic phenotyping of offspring into childhood
and young adulthood are needed to elucidate if SDB exposure that
increases risk for future offspring metabolic disease as studies in
rodents suggest.
Discussion
SDB is a common problem that worsens throughout pregnancy.
Outside of pregnancy, SDB is often associated with obesity, a
metabolic syndrome characterized by IR, glucose, and triglyceride
elevations that are expected to enhance fetal growth. However,
obese women are also at risk of endothelial dysfunction, hypertensive disorders, placental insufficiency and the development of preeclampsia, which could attenuate fetal growth independent of the
effect of SDB. Although mechanistic studies using rodent models
of SF and IH during pregnancy suggest that these exposures
negatively impact long-term offspring metabolic outcomes, investigations in humans have been discrepant, focused mainly on BW,
and lacked a focus linking underlying mechanisms to long-term
outcomes of gestational SDB exposure. Further, all studies in
humans were descriptive. While most investigators made an effort
to control for known confounding factors (n = 32; Table 3), there is
significant possibility that unmeasured and unknown variables
could influence the study outcomes. Despite these limitations,
the overall evidence suggests a link between SDB, characterized
by IH, SF or both, and offspring SGA and LGA, both of which
are related to increased future obesity and metabolic disease risk.
Rodent models suggested that pathophysiological changes
accompanying SDB during pregnancy may have lasting effects
on metabolic regulation in offspring, and BW in offspring may
not demonstrate the true deleterious effects of exposure to
gestational SDB. Indeed, mice born to mothers exposed to SF
had similar BW to control mice; however, as the mice reached
adulthood, the exposed mice had significantly more metabolic
abnormalities.54–56,59 Further, animal models suggested that SDB
exposure may have a sex-dependent effect.49,55,59 This supports
previous findings that males may be more vulnerable to short-term
changes or exposures in the womb, while females may not manifest
differences until later, especially in the context of postnatal longer
term exposures.109 There are many limitations to rodent models.
Rodent gestation demonstrates marked differences in placental
development which result in no spontaneous preeclampsia. The
further birth of multiple pups with minimal fat mass at birth,
and the strong influence of postnatal development(including fat
accretion) make translation to human pregnancies difficult.
Importantly, rodents do not spontaneously develop SDB.
Instead, investigators mimicked a condition that would not normally exert influence on rodent physiology. Thus, growth and body
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composition in rodents at birth will not closely reflect what could
be expected in humans. Despite these limitations, rodent models
support that exposure to gestational SDB may have negative
long-term outcomes for the metabolic health of the offspring.
Studies in humans suggested a link between maternal SDB
and both SGA and LGA, but a number of considerations impact
interpretation of the data. A salient problem across human
studies was inconsistency in reporting of infant outcomes.
Measurement of SDB also varied widely. While some studies used
objective measurement of SDB (such as laboratory or in home
polysomnography),65,69,74,79,85,87 others used a single question
about presence of snoring.1,4,7,72,77,84 Importantly, the majority of
studies were not powered to detect a relationship between
SDB and infant outcomes. Only five were powered on an infant
outcome,13,31,65,71,78 and none on infant body composition.
Investigators found an association in three of the studies and no
association in two (Table 2). Thus, many studies may not have
detected an association due to inadequate power. Timing of
SDB assessment varied widely across studies in humans.
Symptoms of SDB (i.e. snoring) were assessed at delivery in many
studies, while others assessed SDB earlier in pregnancy. Severity of
SDB was not typically reported. It is speculated that women who
enter pregnancy with chronic OSA have higher risk for altered placental function that would result in compromised nutrient supply
and placental perfusion as well as fetal under-development and
growth restriction. Alternatively, we hypothesize that mild SDB
without significant hypoxemia and a deleterious effect on placental
development may exacerbate pregnancy IR, promoting nutrient
excess and fetal overgrowth (Fig. 1). It is possible, and highly likely,
that mild SDB either develops or worsens over pregnancy in those
affected by obesity, but in many, never becomes severe enough to
compromise placental development and perfusion. Thus, while
mild IH and SF are speculated to increase oxidative stress and
inflammation to some degree, the placenta may still develop normally. If maternal IH and/or SF worsen IR, excess fetal nutrient
exposure may result in LGA. Alternatively, with more severe IH,
placental insufficiency may attenuate fetal overgrowth in spite of
an effect on worsening maternal IR and nutrient excess in late gestation. Assessment of SDB symptoms (i.e. presence/absence of
snoring) only at the end of pregnancy provides incomplete information about the timing and severity of an exposure that evolved
over gestation. It is also possible that SDB serves as a marker for
other underlying conditions, such as obesity, gestational hypertension, IR, inflammation, or elevated glucose levels, which mediate
many of the alterations in birth outcomes. Future, more highly
controlled, studies in which SDB is objectively categorized into
mild/moderate or severe OSA, its occurrence measured in in the
1st, 2nd, and 3rd trimesters, and its associated complications
including IR, inflammation, hypoxia, oxidative stress, altered
glucose and lipid metabolism, elevated blood pressure, and endothelial dysfunction are better quantified will help to delineate if
there truly are opposing effects of the SDB spectrum on infant outcomes, allowing for better understanding of SDB as an exposure.
Based on rodent models, it is also possible that BW may be
normal in infants exposed to SDB in utero, but body composition
(percentage of body fat) may differ.110 Higher neonatal adiposity is
associated with increased risk for childhood obesity. Results from
our lab indicate a potential relationship between severity of maternal OSA and infant adiposity. In a recent study, we found that
infant % body fat, measured at 2 weeks postpartum, was significantly correlated with overnight oxygen desaturation in a group
of women with obesity who had previously undiagnosed mild
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OSA, possibly mediated by higher 24-h glycemic patterns as
measured by continuous glucose monitoring.95 We also found a
positive correlation between OSA severity and fasting free fatty
acids as well as hepatic IR,95 suggesting potential mechanisms
by which SDB exacerbates IR in the mother and contributes to
excessive infant adiposity. Future studies should include measurement of infant body composition as infant adiposity to provide a
stronger indicator of future disease risk rather than BW alone.44
Mechanistic studies in humans looking at the effects of SDB
during pregnancy showed evidence of hypoxia at the level of the
placenta, increased inflammation and oxidative stress, and suggested increased risk of disease development in the offspring
(telomere length). However, these studies are limited by very small
sample sizes, lack of objective measurement of SDB, and were not
carefully controlled. Controlled studies in which participants are
carefully enrolled based on like phenotypes are needed to
elucidate mechanisms behind the relationship between SDB,
inflammation and IR, such as the role of HIF1-α, a transcription
factor induced by hypoxia, linked to both inflammation and IR.
In Fig. 1, we highlight other potential mechanisms by which
SDB could exacerbate IR including at the level of smooth muscle,
adipose tissue, or the liver, as well as effects on hormones, such as
GLP-1 and cortisol, and sympathetic stimulation.
In summary, prevailing evidence across human and rodent
models implicates in utero exposure to SDB as a developmental
origin of future metabolic health. Since OSA is tightly linked to
obesity, prenatal screening of obese pregnant women for risk of
SDB may help to identify women who have undiagnosed OSA
for treatment prior to pregnancy. Prenatal counseling that directly
promotes weight loss prior to pregnancy may help to further
prevent worsening SDB with pregnancy. Treatment of SDB may
be important to eliminate the exposure of hypoxia and alleviate
exacerbation of the IR of pregnancy resulting in altered glucose
and lipid metabolism and inflammation. While there remain no
large prospective studies in humans investigating the impact of
SDB treatment on offspring outcomes, the evidence suggests that
treatment targeting factors such as IH and SF may reduce future
offspring disease risk. Prospective human trials over the course of
pregnancy designed to discern the mechanistic pathways by which
SDB influences placental development, fetal growth, and future risk
of offspring metabolic disease are of paramount importance to
inform timing and type of interventional therapy. With the everrising prevalence of obesity both in pregnancy and in childhood,
understanding if SDB during pregnancy, still largely unrecognized
in clinical practice, has important long-term implications for offspring is vital as it may be one modifiable contributor of significant
morbidity from metabolic disorders in adulthood.
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